| GTO ID | GTC2216 |
| Trial ID | NCT04135092 |
| Disease | Metastatic Cancer |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| Phase | Phase2 |
| Recruitment status | No Longer Available |
| Title | Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab |
| Year | 2019 |
| Country | United States |
| Company sponsor | National Institutes of Health Clinical Center (CC) |
| Other ID(s) | 209950 |
| Cohort 1 | |||||||||
|
|||||||||